BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ACAD upcoming catalysts

ACADIA PHARMS INC: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 4 FDA event(s). Subscribe to ACAD (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-27FDA approvalapprovedACADIA PHARMS INC ACADNUPLAZIDApproved 2026-04-27: NUPLAZID (NDA207318 SUPPL16)
2026-04-27FDA approvalapprovedACADIA PHARMS INC ACADNUPLAZIDApproved 2026-04-27: NUPLAZID (NDA210793 SUPPL14)
2026-03-27FDA approvalapprovedACADIA PHARMS INC ACADDAYBUEApproved 2026-03-27: DAYBUE (NDA217026 SUPPL8)
2025-12-11FDA approvalapprovedACADIA PHARMS INC ACADDAYBUE STIXApproved 2025-12-11: DAYBUE STIX (NDA219884 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-12-19P3ACADIA Pharmaceuticals Inc. ACADNCT06420297 OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeHyperphagia in Prader-Willi Syndrometerminated168

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.